{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:40:19Z","timestamp":1777520419914,"version":"3.51.4"},"reference-count":21,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"published-print":{"date-parts":[[2008]]},"abstract":"<jats:p>Aggressive natural killer (NK) cell leukemia (ANKL) is a prototype of an Epstein-Barr virus (EBV)-associated lymphoid malignancy, which is characterized by a fulminant clinical course and a median survival interval &lt;2 months. EBV negativity in ANKL is uncommon, and the characteristics of EBV-negative ANKL are not well defined. We compared the clinicopathological characteristics of EBV-negative ANKL patients (group 1, n = 2) with those of EBV-positive ANKL patients (group 2, n = 14) and reviewed the literature for reports on EBV-negative ANKL cases. EBV-negative and EBV-positive ANKL patients had similar clinical and pathological characteristics, but EBV-negative patients had a longer survival than EBV-positive patients (11.5 vs. 1.5 months, respectively). EBV-negative patients achieved complete remission, but tumors often relapsed after a short interval. In conclusion, EBV-negative ANKL is an uncommon malignancy that pursues a less aggressive clinical course than EBV-positive ANKL.<\/jats:p>","DOI":"10.1159\/000193225","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T08:53:22Z","timestamp":1232441602000},"page":"199-206","source":"Crossref","is-referenced-by-count":30,"title":["Aggressive Natural Killer Cell Leukemia: Is Epstein-Barr Virus Negativity an Indicator of a Favorable Prognosis?"],"prefix":"10.1159","volume":"120","author":[{"given":"Young Hyeh","family":"Ko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghui","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,1,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080%2F10428190400004513"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2353%2Fjmoldx.2006.050152"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3109%2F10428190009054881"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2230.2005.01986.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2141.1998.01109.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2257.2000.00284.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016%2FS0165-4608%2801%2900474-5"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097%2F01.pas.0000168510.54867.9a"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159%2F000205617"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2141.1990.tb02615.x"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159%2F000040955"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2559.2000.00936.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080%2F10428190500032273"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136%2Fjcp.49.12.1011"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1532%2FIJH97.A10612"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11864-003-0004-0"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.leu.2403262"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1349-7006.2006.00155.x"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood-2007-01-067769"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2141.1998.00606.x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080%2F10428190802087454"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/193225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/193225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T23:29:31Z","timestamp":1745450971000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000193225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,3,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000193225","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008]]}}}